|
70 Companies |
|
97 Products |
|
97 Products |
|
124 Mechanisms of Action |
|
1 Trial |
|
1962 News |
|
| «12...28293031323334353637383940» |
- Trial completion: Methadone Maintenance & HIV Risk in Ukraine (clinicaltrials.gov) - Jan 16, 2012
P3, N=50, Completed, Sponsor: University of Pennsylvania
Recruiting --> Completed
- | metadoxine / Generic mfg.
New P2 trial: A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease (clinicaltrials.gov) - Jan 3, 2012
P2, N=83, Recruiting, Sponsor: Brown University
- lisdexamfetamine / Generic mfg.
Enrollment open: Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence (clinicaltrials.gov) - Jan 3, 2012
P1/2, N=12, Recruiting, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed Not yet recruiting --> Recruiting
- doxazosin mesylate / Generic mfg.
Enrollment open: Doxazosin an a1 Antagonist for Alcohol Dependence (clinicaltrials.gov) - Jan 3, 2012
P2, N=60, Recruiting, Sponsor: Brown University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- New P1 trial: RAFIKI: A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention (clinicaltrials.gov) - Jan 2, 2012
P1, N=336, Recruiting, Sponsor: Brown University
- Trial completion: Reducing Health Problems Associated With Injection Drug Use (clinicaltrials.gov) - Jan 2, 2012
P=N/A, N=87, Completed, Sponsor: University of Northern Colorado
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial withdrawal: Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates (clinicaltrials.gov) - Dec 29, 2011
P=N/A, N=0, Withdrawn, Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting --> Completed Completed --> Withdrawn
- Enrollment change: Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates (clinicaltrials.gov) - Dec 29, 2011
P=N/A, N=0, Withdrawn, Sponsor: National Institute on Drug Abuse (NIDA)
Completed --> Withdrawn N=80 --> 0
- Enrollment change: SCHIZOCAN: Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=97, Active, not recruiting, Sponsor: Assistance Publique - H
N=80 --> 0 N=330 --> 97
- Enrollment closed: SCHIZOCAN: Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=97, Active, not recruiting, Sponsor: Assistance Publique - H
N=330 --> 97 Recruiting --> Active, not recruiting
- | New P4 trial: EPALD: Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease (clinicaltrials.gov) - Dec 26, 2011
P4, N=120, Recruiting, Sponsor: Chuncheon Sacred Heart Hospital
- Clinical: ODHIN_RCT: Trial Testing the Effect of Strategies on Performance of Brief Intervention Programmes for Harmful Alcohol Consumption (clinicaltrials.gov) - Dec 15, 2011
P=N/A, N=120, Enrolling by invitation, Sponsor: Fundacion Clinic per a la Recerca Biomédica
- Emsam (selegiline transdermal) / Viatris
New P2 trial: Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior (clinicaltrials.gov) - Dec 15, 2011
P2, N=12, Completed, Sponsor: Midwest Biomedical Research Foundation
- Clinical: Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=389, Recruiting, Sponsor: Centre Hospitalier Esquirol
- Enrollment open: MATRIS: Malm (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=130, Recruiting, Sponsor: Region Skane
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- risperidone / Generic mfg., desipramine / Generic mfg.
Trial initiation date: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Dec 8, 2011
P2, N=40, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting Initiation date: Aug 2011 --> Dec 2011
- levetiracetam / Generic mfg.
Enrollment change: Levetiracetam for the Treatment of Alcohol Dependence and Anxiety (clinicaltrials.gov) - Dec 8, 2011
P2, N=3, Completed, Sponsor: New York State Psychiatric Institute
Initiation date: Aug 2011 --> Dec 2011 N=30 --> 3
- risperidone / Generic mfg., desipramine / Generic mfg.
Enrollment open: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Dec 8, 2011
P2, N=40, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
N=30 --> 3 Not yet recruiting --> Recruiting
- | Enrollment change: Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders (clinicaltrials.gov) - Dec 6, 2011
P3, N=60, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=160 --> 60
- | Trial completion: Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders (clinicaltrials.gov) - Dec 6, 2011
P3, N=60, Completed, Sponsor: University of California, San Francisco
N=160 --> 60 Recruiting --> Completed
- lisdexamfetamine / Generic mfg.
New P1/2 trial: Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence (clinicaltrials.gov) - Dec 5, 2011
P1/2, N=12, Recruiting, Sponsor: New York State Psychiatric Institute
- ||| Trial completion: Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke (clinicaltrials.gov) - Dec 4, 2011
P1, N=109, Completed, Sponsor: Rock Creek Pharmaceuticals, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: DDAT: SPECT Imaging of DAT Genotype (clinicaltrials.gov) - Dec 1, 2011
P1, N=40, Recruiting, Sponsor: University of Pennsylvania
- bupropion / Generic mfg.
Trial completion: Smoking Cessation Intervention: Effectiveness in Primary Care (clinicaltrials.gov) - Nov 28, 2011
P4, N=1346, Completed, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P2 trial: A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence (clinicaltrials.gov) - Nov 24, 2011
P2, N=450, Recruiting, Sponsor: A. Eden Evins
- Trial completion: Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment (clinicaltrials.gov) - Nov 17, 2011
P2, N=183, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Group-Based Contingency Management for Substance Abuse Treatment - 1 (clinicaltrials.gov) - Nov 17, 2011
P=N/A, N=312, Completed, Sponsor: University of Connecticut Health Center
Active, not recruiting --> Completed Recruiting --> Completed
- | New P4 trial: Emerging Adults Who Use Alcohol and Marijuana (clinicaltrials.gov) - Nov 15, 2011
P4, N=500, Recruiting, Sponsor: Butler Hospital
- Vivitrol (naltrexone extended-release injectable suspension) / Alkermes
New P4 trial, Adverse events: XRNT: Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT (clinicaltrials.gov) - Nov 13, 2011
P4, N=40, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- |||||||||| New P3 trial: Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure (clinicaltrials.gov) - Nov 9, 2011
P3, N=200, Recruiting, Sponsor: Vital Therapies, Inc.
- || New P2/3 trial: Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence (clinicaltrials.gov) - Nov 7, 2011
P2/3, N=100, Recruiting, Sponsor: New York State Psychiatric Institute
- Intuniv (guanfacine XR) / Shionogi, Takeda
New P1 trial: Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence (clinicaltrials.gov) - Nov 7, 2011
P1, N=20, Recruiting, Sponsor: New York State Psychiatric Institute
- acetylcysteine solution / Generic mfg.
Trial completion: Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1 (clinicaltrials.gov) - Nov 7, 2011
P2, N=235, Completed, Sponsor: Medical University of South Carolina
Recruiting --> Completed Recruiting --> Completed
- | olanzapine / Generic mfg.
Trial completion: A New Pharmacotherapy for Alcohol Dependence: Olanzapine (clinicaltrials.gov) - Nov 3, 2011
P3, N=304, Completed, Sponsor: The Mind Research Network
Recruiting --> Completed Recruiting --> Completed
- | New P1/2 trial: Monitoring and Feedback in Substance Abuse Treatment (clinicaltrials.gov) - Oct 31, 2011
P1/2, N=327, Completed, Sponsor: Treatment Research Institute
- dronabinol oral / Generic mfg.
Trial completion: Dronabinol Treatment for Marijuana Addiction (clinicaltrials.gov) - Oct 30, 2011
P2, N=156, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed Recruiting --> Completed
- || New P3 trial: Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders (clinicaltrials.gov) - Oct 20, 2011
P3, N=80, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- || New P3 trial: Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment (clinicaltrials.gov) - Oct 20, 2011
P3, N=443, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
- New P1 trial, Metastases: Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer (clinicaltrials.gov) - Oct 20, 2011
P1, N=10, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- dextroamphetamine immediate release / Generic mfg.
Enrollment closed: DDC: Marijuana Drug Discrimination and Self-Administration (clinicaltrials.gov) - Oct 19, 2011
P=N/A, N=25, Active, not recruiting, Sponsor: Wayne State University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Buprenex (buprenorphine) / Reckitt Benckiser
Trial completion: Buprenorphine for the Treatment of Neonatal Abstinence Syndrome (clinicaltrials.gov) - Oct 19, 2011
P1, N=60, Completed, Sponsor: Thomas Jefferson University
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Chantix (varenicline) / Pfizer
Trial completion: Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study) (clinicaltrials.gov) - Oct 17, 2011
P3, N=117, Completed, Sponsor: Queen Mary University of London
Recruiting --> Completed Recruiting --> Completed
- | Vivitrol (naltrexone extended-release injectable suspension) / Alkermes
New P4 trial: A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration (clinicaltrials.gov) - Oct 13, 2011
P4, N=30, Active, not recruiting, Sponsor: Alkermes
- methamphetamine / Generic mfg.
Enrollment change: Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men (clinicaltrials.gov) - Oct 12, 2011
P2, N=53, Completed, Sponsor: Friends Research Institute, Inc.
Recruiting --> Completed N=40 --> 53
- Enrollment change: Computer-based Brief Intervention for Perinatal Substance Abuse (clinicaltrials.gov) - Oct 12, 2011
P1/2, N=143, Completed, Sponsor: Wayne State University
N=40 --> 53 N=500 --> 143
- venlafaxine / Generic mfg.
Enrollment change: Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1 (clinicaltrials.gov) - Oct 12, 2011
P2, N=123, Completed, Sponsor: New York State Psychiatric Institute
N=500 --> 143 N=180 --> 123
- Trial completion: Computer-based Brief Intervention for Perinatal Substance Abuse (clinicaltrials.gov) - Oct 12, 2011
P1/2, N=143, Completed, Sponsor: Wayne State University
N=180 --> 123 Recruiting --> Completed
- selegiline / Generic mfg.
Trial termination: Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence (clinicaltrials.gov) - Oct 6, 2011
P=N/A, N=40, Terminated, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Completed Active, not recruiting --> Terminated; Preliminary results did not support the utility of combining selegeline + NRT.
- | Vivitrol (naltrexone extended-release injectable suspension) / Alkermes
New P2 trial: Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) (clinicaltrials.gov) - Oct 6, 2011
P2, N=100, Recruiting, Sponsor: San Francisco Department of Public Health
- | GSK1521498 / GSK
Trial completion: GSK1521498 Alcohol Interaction Study (clinicaltrials.gov) - Oct 6, 2011
P1, N=28, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; Preliminary results did not support the utility of combining selegeline + NRT. Active, not recruiting --> Completed